SCHEMBL17154397

SCHEMBL17154397

Nc1cccc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 8/20 0.68
KMT2A Q03164 4/20 0.67
MEN1 O00255 2/20 0.67
GFER P55789 2/20 0.67
POLB P06746 2/20 0.67
RAD52 P43351 2/20 0.67
TOP2A P11388 3/20 0.61
TOP2B Q02880 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
KDM4E B2RXH2 2/20 0.59
GAA P10253 2/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
AHR P35869 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18407164 0.86 TOP2A (0.73) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL7521911 0.86 MEN1 (0.67) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL902770 0.82 KDM1A (1.00) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL14116117 0.81 KMT2A (0.97) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL17154450 0.81 KDM1A (1.00) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL17154394 0.81 KDM1A (0.84) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL18407155 0.80 KDM1A (0.68) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL14116115 0.80 KDM1A (0.68) KDM1AKMT2AMEN1GFERPOLB
Hydrochloric Acid SCHEMBL15673452 0.80 KDM1A (0.96) KDM1AKMT2AMEN1GFERPOLB
SCHEMBL4909608 0.80 TOP2A (0.64) KDM1AKMT2AMEN1GFERPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183912-B2 HDMX inhibitors and their use for cancer treatment MiRx Pharmaceuticals, LLC (US) 2019-01-22 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
WO-2015153535-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MiRx Pharmaceuticals, LLC (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT TP53, DDX3X, API5 KDM1A 702/4885KMT2A 1544/4885MEN1 2446/4885
US-10183912-B2 HDMX inhibitors and their use for cancer treatment TP53, MDM4, MDM2 KDM1A 650/4885KMT2A 1514/4885MEN1 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.